Welcome to Cellula BioPharma

Cellula BioPharma is developing a game changing CAR-T platform technology for solid tumors. 

Unmet Need

Our CAR-T technology

CAR T cell therapy has represented an exciting breakthrough in the treatment of patients with hematologic malignancies leading to the FDA approval of six CAR-T products.

​To date, >200 registered CAR T cell clinical trails against solid tumor showed that the antitumor activity of CAR-T in solid tumors is very disappointing.

We have developed a game changing CAR T cell therapy platform suitable for solid tumors

• Nucleotide Metabolic Reprogramed CAR (designated as MRCAR)
• Efficacy and safety validated using in vitro assays and two different tumor mouse models

Our team is comprised of experienced serial entrepreneurs, investigators, and physicians with the necessary VC, GMP, and clinical resources. "

Development of MR-CAR T cell therapy

Differentiation 1: INO is superior to current cytokine strategies for promoting T cell persistence 

• Current cytokine strategies have failed to improve T cells that are starving in solid tumors  
• Nutrients play an irreplaceable role in CAR T cell therapy

Differentiation 2: MR-CAR-T is superior to ADO blockers to overcome ADO-mediated immunosuppression

• Current ADO blockers only target one of the ADO producing pathway or the receptors
• Our approach has the potential to inhibit ADO completely